2009

• American College of Clinical Pharmacology Position Statement on Direct-to-Consumer/Patient Advertising of Genetic Testing

2007

• American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug Development Process
  

2005

• ACCP Letter of Comment on 2005 Best Pharmaceuticals for Children Act (BPCA) (04/28/2005)

2004

• ACCP Response Letter to FDA Critical Path Paper (07/01/04)

2003

• Asthma-Separating Fact From Fiction
• A Rational Look At Progress vs. The Precautionary Principle
• Epidemiology In Decision-Making How Epidemiology Can Be Properly Used in Decision-Making - Its Strengths and Limitations
• How Can I Judge Good Science?
• The Annapolis Accords for Cost-Benefit Analysis Principles to Judge a Cost-Benefit Analysis
• The Annapolis Accords for Risk Assessment A Citizen's Guide For Risk Assessment and Risk Management, A Set Of Principles To Guide a Risk Analysis
• The Use of Toxicology in Risk Assessment and Decision-Making - Its Strengths and Limitations

2002

• A special supplement released by The Journal of Clinical Pharmacology on the clinical consequences of Marijuana use (10/21/2002)
• The Use of Toxicology in Risk Assessment and Decision-Making for Therapeutic Development

2000

ACCP Response to IOM Report

• ACCP Response to Institute of Medicine Report, "To Err is Human: Building a Safer Health System"

• "Clinical Pharmacology: A Retrospective View of the Future"